(Q85407207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

Lawrence Serfaty

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

Clinics and research in hepatology and gastroenterology

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

36 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

S53-60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

Incidence of gastrointestinal cancers in France

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Genetic alterations during colorectal-tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Aspirin and the Risk of Colorectal Cancer in Women

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Nonsteroidal antiinflammatory drugs and colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Aspirin use and reduced risk of fatal colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Chemoprevention of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

A randomized trial of aspirin to prevent colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Unconjugated secondary bile acids in the serum of patients with colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Increased serum deoxycholic acid levels in men with colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

A prospective study of serum bile acid concentrations and colorectal cancer risk in post-menopausal women on the island of Guernsey.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Relationship between duodenal bile acids and colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Colonic absorption of secondary bile-acids in patients with adenomatous polyps and in matched controls

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Fecal primary bile acids and serum cholesterol are associated with colorectal adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

The effect of ursodesoxycholic acid on duodenal adenomas in familial adenomatous polyposis: a prospective randomized placebo-control trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Bile salt stimulation of colonic epithelial proliferation. Evidence for involvement of lipoxygenase products

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Insights into lipid raft structure and formation from experiments in model membranes

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

A G protein-coupled receptor responsive to bile acids

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Aberrant crypt foci in colon cancer epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Aberrant crypt foci of the colon as precursors of adenoma and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

EGF induces coalescence of different lipid rafts

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS2210-7401%2812%2970022-0

7 January 2021

10.1016/S2210-7401(12)70022-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23141895%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference